2020年3月1日至6月30日期间，通过美国2019冠状病毒病相关住院监测网络确定的住院患者中正在使用的COVID-19研究性治疗方法。
COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020.
作者信息
Acosta Anna M, Mathis Adria L, Budnitz Daniel S, Geller Andrew I, Chai Shua J, Alden Nisha B, Meek James, Anderson Evan J, Ryan Patricia, Kim Sue, Como-Sabetti Kathryn, Torres Salina, Dufort Elizabeth, Bennett Nancy M, Billing Laurie M, Sutton Melissa, Keipp Talbot H, George Andrea, Pham Huong, Hall Aron J, Fry Alicia, Garg Shikha, Kim Lindsay
机构信息
COVID-NET Surveillance Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
All Native Synergies Company, Winnebago, Nebraska, USA.
出版信息
Open Forum Infect Dis. 2020 Nov 9;7(11):ofaa528. doi: 10.1093/ofid/ofaa528. eCollection 2020 Nov.
Using a coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network, we found that 42.5% of hospitalized COVID-19 cases with available data from March 1-June 30, 2020, received ≥1 COVID-19 investigational treatment. Hydroxychloroquine, azithromycin, and remdesivir were used frequently; however, hydroxychloroquine and azithromycin use declined over time, while use of remdesivir increased.
通过一个2019冠状病毒病（COVID-19）相关住院监测网络，我们发现，在2020年3月1日至6月30日有可用数据的住院COVID-19病例中，42.5%接受了≥1种COVID-19研究性治疗。羟氯喹、阿奇霉素和瑞德西韦使用频繁；然而，羟氯喹和阿奇霉素的使用随时间减少，而瑞德西韦的使用增加。
Zotero 插件